Dogwood Therapeutics, Inc. (NasdaqCM: DWTX)
Health Care · Biotechnology · US
$2.68
+7.63% today · -50.8% 1Y
Dogwood Therapeutics, Inc. (NasdaqCM: DWTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $84.64M and employs 8 people.
Over the last twelve months the share price has lost 50.8%, trading between 1.28 and 9.50.
Tweenvest scores Dogwood Therapeutics, Inc. across four factors: quality 32/100. Its strongest factor is quality.
DWTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $84.64M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.71
- Dividend yield
- —
- Beta (5Y)
- 1.76
- 52-week high
- $9.50
- 52-week low
- $1.28
- Avg volume (3M)
- —
- Shares outstanding
- 33.99M
- Employees
- 8
- Next earnings
- —
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
- ISIN
- US92829J2033
- Founded
- 2012
- Listed since
- Dec 17, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.